TY  - JOUR
AU  - Gonzalez-Cao, Maria
AU  - Mayo Casas, Clara
AU  - Oramas, Juana
AU  - Berciano-Guerrero, Miguel A.
AU  - de la Cruz, Luis
AU  - Cerezuela, Pablo
AU  - Arance, Ana
AU  - Munoz-Couselo, Eva
AU  - Espinosa, Enrique
AU  - Puertolas, Teresa
AU  - Diaz Beveridge, Roberto
AU  - Ochenduszko, Sebastian
AU  - Villanueva, Maria-Jose
AU  - Basterretxea, Laura
AU  - Bellido, Lorena
AU  - Rodriguez, Delvys
AU  - Campos, Begona
AU  - Montagut, Clara
AU  - Drozdowskyj, Ana
AU  - Molina, Miguel A.
AU  - Antonio Lopez-Martin, Jose
AU  - Berrocal, Alfonso
PY  - 2021
DO  - 10.1038/s41467-021-26572-6
UR  - https://hdl.handle.net/10668/27003
T2  - Nature communications
AB  - Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these...
LA  - en
PB  - Nature portfolio
KW  - Mek inhibition
KW  - Double-blind
KW  - Vemurafenib
KW  - Efficacy
TI  - Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
TY  - research article
VL  - 12
ER  -